Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines (Q38538837)

3 September 2017

1 reference

title

Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines (English)

1 reference

3 September 2017

1 reference

2

Nancy M Bennett

1 reference

3 September 2017

Tamara Pilishvili

1

1 reference

PubMed ID

26116257

3 September 2017

language of work or name

English

0 references

publication date

23 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

33 Suppl 4

1 reference

3 September 2017

D60-5

1 reference

Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008.

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Efficacy of pneumococcal vaccination in adults: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Pneumococcal infection in adults: burden of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.102

10.1016/J.VACCINE.2015.05.102

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

26116257